Literature DB >> 32274579

Novel Native and Engineered Botulinum Neurotoxins.

Lance Steward1, Mitchell F Brin1,2, Amy Brideau-Andersen3.   

Abstract

Botulinum neurotoxins (BoNTs), produced by Clostridia and other bacteria, are the most potent toxins known. Their cleavage of the soluble N-ethylmaleimide-sensitive factor activating protein receptor (SNARE) proteins in neurons prevents the release of neurotransmitters, thus resulting in the muscle paralysis that is characteristic of botulism. This mechanism of action has been exploited for a variety of therapeutic and cosmetic applications of BoNTs. This chapter provides an overview of the native BoNTs, including the classical serotypes and their clinical use, mosaic BoNTs, and novel BoNTs that have been recently identified in clostridial and non-clostridial strains. In addition, the modular structure of native BoNTs, which are composed of a light chain and a heavy chain, is amenable to a multitude of novel fusions and mutations using molecular biology techniques. These novel recombinant BoNTs have been used or are being developed to further characterize the biology of toxins, to assist in vaccine production, to serve as delivery vehicles to neurons, and to be utilized as novel therapeutics for both neuronal and non-neuronal cells.

Entities:  

Keywords:  AbobotulinumtoxinA; Botulinum toxin; IncobotulinumtoxinA; Neurotoxin; OnabotulinumtoxinA; PrabotulinumtoxinA-xvfs; Recombinant; RimabotulinumtoxinB

Year:  2021        PMID: 32274579     DOI: 10.1007/164_2020_351

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  117 in total

1.  Notes on Bacillus botulinus.

Authors:  G S Burke
Journal:  J Bacteriol       Date:  1919-09       Impact factor: 3.490

2.  Injectable DaxibotulinumtoxinA for the Treatment of Glabellar Lines: A Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter Comparison With OnabotulinumtoxinA and Placebo.

Authors:  Jean Carruthers; Nowell Solish; Shannon Humphrey; Nathan Rosen; Channy Muhn; Vince Bertucci; Arthur Swift; Andrei Metelitsa; Roman G Rubio; Jacob Waugh; John Quiring; Gill Shears; Alastair Carruthers
Journal:  Dermatol Surg       Date:  2017-11       Impact factor: 3.398

3.  Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.

Authors:  M F Brin; M F Lew; C H Adler; C L Comella; S A Factor; J Jankovic; C O'Brien; J J Murray; J D Wallace; A Willmer-Hulme; M Koller
Journal:  Neurology       Date:  1999-10-22       Impact factor: 9.910

4.  Covalent structure of botulinum neurotoxin type E: location of sulfhydryl groups, and disulfide bridges and identification of C-termini of light and heavy chains.

Authors:  B S Antharavally; B R DasGupta
Journal:  J Protein Chem       Date:  1997-11

5.  Holotoxin Activity of Botulinum Neurotoxin Subtype A4 Originating from a Nontoxigenic Clostridium botulinum Expression System.

Authors:  Marite Bradshaw; William H Tepp; Regina C M Whitemarsh; Sabine Pellett; Eric A Johnson
Journal:  Appl Environ Microbiol       Date:  2014-09-19       Impact factor: 4.792

6.  Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates.

Authors:  Steffen Bade; Andreas Rummel; Clemens Reisinger; Tino Karnath; Gudrun Ahnert-Hilger; Hans Bigalke; Thomas Binz
Journal:  J Neurochem       Date:  2004-12       Impact factor: 5.372

7.  A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins.

Authors:  Jason R Barash; Stephen S Arnon
Journal:  J Infect Dis       Date:  2013-10-07       Impact factor: 5.226

8.  Recombinant derivatives of botulinum neurotoxin A engineered for trafficking studies and neuronal delivery.

Authors:  Philip A Band; Steven Blais; Thomas A Neubert; Timothy J Cardozo; Konstantin Ichtchenko
Journal:  Protein Expr Purif       Date:  2010-01-04       Impact factor: 1.650

Review 9.  Botulinum toxin type A products are not interchangeable: a review of the evidence.

Authors:  Mitchell F Brin; Charmaine James; John Maltman
Journal:  Biologics       Date:  2014-10-06

10.  Identification of a novel botulinum neurotoxin gene cluster in Enterococcus.

Authors:  Jason Brunt; Andrew T Carter; Sandra C Stringer; Michael W Peck
Journal:  FEBS Lett       Date:  2018-01-23       Impact factor: 4.124

View more
  6 in total

Review 1.  Making the cut with protease engineering.

Authors:  Rebekah P Dyer; Gregory A Weiss
Journal:  Cell Chem Biol       Date:  2021-12-17       Impact factor: 9.039

Review 2.  Engineering Botulinum Neurotoxins for Enhanced Therapeutic Applications and Vaccine Development.

Authors:  Christine Rasetti-Escargueil; Michel R Popoff
Journal:  Toxins (Basel)       Date:  2020-12-22       Impact factor: 4.546

Review 3.  Botulinum Neurotoxin Therapy for Depression: Therapeutic Mechanisms and Future Perspective.

Authors:  Yang Li; Tong Liu; Weifeng Luo
Journal:  Front Psychiatry       Date:  2021-04-23       Impact factor: 4.157

4.  Recombinant botulinum neurotoxin serotype A1 in vivo characterization.

Authors:  Cindy Périer; Vincent Martin; Sylvie Cornet; Christine Favre-Guilmard; Marie-Noelle Rocher; Julien Bindler; Stéphanie Wagner; Emile Andriambeloson; Brian Rudkin; Rudy Marty; Alban Vignaud; Matthew Beard; Stephane Lezmi; Mikhail Kalinichev
Journal:  Pharmacol Res Perspect       Date:  2021-10

Review 5.  Botulinum Neurotoxins in Central Nervous System: An Overview from Animal Models to Human Therapy.

Authors:  Siro Luvisetto
Journal:  Toxins (Basel)       Date:  2021-10-22       Impact factor: 4.546

6.  Structural Analysis of Botulinum Neurotoxins Type B and E by Cryo-EM.

Authors:  Sara Košenina; Markel Martínez-Carranza; Jonathan R Davies; Geoffrey Masuyer; Pål Stenmark
Journal:  Toxins (Basel)       Date:  2021-12-23       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.